Study details
Enrolling now
Metformin for People With CFRD on CFTR Modulator Therapy to Improve Ion Channel Function
University of Kansas Medical Center
NCT IDNCT04530383ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Ages
18+
Locations
1 site in KS
About this study
This Phase 2 study is testing Metformin Hydrochloride in people with cystic fibrosis. The primary outcome being measured is Change in BK channel gene expression.
Based on ClinicalTrials.gov records.
PhasePhase 2
DrugMetformin Hydrochloride
Routeoral
Primary goalChange in BK channel gene expression
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low15%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Drug classes
Blood Glucose Regulators (Insulin Receptor Agonists)
Drug routes
oral (Oral Tablet)
Endpoints
Primary: Change in BK channel gene expression
Secondary: Change in Quality of Life (CFQ-R), Change in receptor for receptor for advanced glycation end products (RAGE) gene expression, Pharmacokinetics of metformin
Body systems
Endocrinology, Respiratory